Skip Navigation Links   >   Home   >   News & Media
31 March 2022

Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

Programme 1 - OCT461201

OCT461201 is being tested in multiple translational models of both neuropathic and visceral pain.

The conclusive analysis of recent pre-clinical data has shown that OCT461201 is well positioned for small fibre neuropathies, as it successfully reduced pain in a model of chemotherapy-induced peripheral neuropathy ("CIPN"). Recent results from other neuropathic pain models suggest OCT461201 may not be effective in post-herpetic neuralgia ("PHN"). The Company is therefore replacing PHN with CIPN as an indication for OCT461201.

In response to these very encouraging data in CIPN, the Company's strategy in neuropathic pain, is to focus on a clinical development programme aimed to benefit patients with small fibre neuropathies, such as cancer patients suffering from nerve damage caused by treatment with chemotherapy, and potentially, patients suffering from diabetic neuropathy.

There is an urgent need for new therapies to treat CIPN as there are currently no approved therapies for this condition. The current standard of care is the off-label use of gabapentinoids (gabapentin and pregabalin) and antidepressants (e.g. duloxetine), drugs associated with serious side effects. Furthermore, in some cases their overall clinical effectiveness is inadequate, leaving cancer patients in pain, with a reduced quality of life and the prospect of having to change or stop their chemotherapy altogether.

The large unmet medical need in patients suffering from CIPN is estimated to have a global market valued at US$1.61bn in 2020 and forecast to reach US$2.37bn by the year 2027, which, in the view of the Directors, could grow to over US$7bn once combined with other small fibre neuropathies.

In addition to CIPN, the Company will continue to develop OCT461201 for visceral pain in patients suffering from irritable bowel syndrome (IBS).

Programme 2 - OCT130401 - Trigeminal Neuralgia Clinical Trial

OCT130401 is a drug-device combination delivering phytocannabinoids ("pCBs") to patients suffering from trigeminal neuralgia ("TN") with a pressurised metered-dose inhaler ("pMDI"). TN causes debilitating and excruciating pain, has a fast and unexpected onset and is difficult to treat with conventional systemic medicines.

OCTP intends to undertake its phase one clinical trials for OCT130401 (currently anticipated in Q4 2022) in healthy volunteers in Australia, in order to benefit from the experience of local Human Research Ethical Committees ("HREC"), medical institutions, and clinical research organisations ("CROs") in supporting and performing clinical trials with pCBs. The Company is currently executing its due diligence process of selecting a partner CRO to expedite the route to first in human trials while ensuring quality and patients' safeguarding.

In addition, OCTP has entered into a five-year Master Service Agreement with Benuvia Manufacturing Inc. ("Benuvia"). The Company anticipates that it will shortly agree a Statement of Work with Benuvia for the manufacture of the drug-device combination for use in phase 1 clinical trials. The manufacture will be in compliance with current good manufacturing practice (cGMP). 

TN is on the rise with between approximately 10,000 and 15,000 new cases in the United States diagnosed each year. The Directors estimate that in 2021 there were between 60,000 and 95,000 people living with the condition in the UK.

Commenting on recent developments, Chief Scientific Officer, Valentino Parravicini said:

"Our research ethos is to develop breakthrough therapies for debilitating pain conditions with significant unmet medical needs. Although we are replacing PHN with CIPN for OCT461201, we are making good progress in line with the strategy stated in our IPO Prospectus and on our revised focus to benefit patients with small fibre neuropathies, such as cancer patients suffering from nerve damage caused by treatment with chemotherapy".

 

    All News

    • Investor Meet Company Q&A Session

      16 May 2022 Investor Meet
    • Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

      25 April 2022 Scientific Advisory Board
    • Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

      31 March 2022 Programme Update
    • Data from pre-clinical study show positive results

      08 March 2022 Research Update
    • Requisition of General Meeting - Update

      04 March 2022 General Meeting
    • Requisition of General Meeting

      18 February 2022 General Meeting
    • Notice of Analyst and Investment Presentation - How to Register

      17 February 2022 Presentations
    • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

      18 November 2021 StemTech
    • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

      17 November 2021 R&D Support
    • Posting of Annual Report, Notice of AGM and Form of Proxy

      27 October 2021 Annual Report, Notice of AGM and Form of Proxy
    • OCT Results and Company Update

      18 October 2021 Results and Company Update
    • Final Results and Notice of Annual General Meeting 13th October 2021

      13 October 2021 RNS
    • Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

      12 October 2021 Trigeminal Neuralgia Interview
    • Oxford Cannabinoid Technologies Targets Chronic Pain Condition with Latest Formulation

      11 October 2021 Program 2 Announcement
    • OCT Explore the Opioid Crisis and Chronic Pain Pandemic in Pharmafocus Magazine

      30 September 2021 Pharmafocus Article
    • Good shape, good budget and on track for Oxford Cannabinoid Technologies Holdings

      28 September 2021 Podcast
    • Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library

      22 September 2021 Canopy Growth
    • Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

      02 September 2021 US Market
    • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

      06 July 2021 Partnership
    • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

      Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

      24 June 2021 iCDP Speaker
    • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

      Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

      22 June 2021 Meet the Team Interview Series
    • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

      04 June 2021 Live Presentation
    • OCT Forges Partnership with Voisin Consulting Life Sciences

      OCT Forges Partnership with Voisin Consulting Life Sciences

      01 June 2021 OCT Partnership
    • Oxford Cannabinoid Technologies Announces Changes to Executive Team

      11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
    • OCT Company Values: How We Pursue Our Mission and Vision

      OCT Company Values: How We Pursue Our Mission and Vision

      01 December 2020 OCT Company Values
    • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

      Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

      26 October 2020 Meet the Team Interview Series
    • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

      07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
    • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

      OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

      28 July 2020 OCT Press Release
    • Cannabinoids in medicine part 5: Treating COVID-19

      17 June 2020 Open Access Government
    • Why the Government should continue to invest in Life Sciences post COVID-19

      Why the government should continue to invest in Life Sciences post COVID-19

      01 June 2020 OCT blog - John Lucas, COO
    • OCT researchers publish new study examining genes involved in treating neuropathic pain

      19 April 2020 OCT Press Release
    • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

      03 April 2020 OCT Press Release
    • Cannabinoids in medicine part 4: Epilepsy

      30 March 2020 Open Access Government
    • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

      07 January 2020 Open Access Government
    • Cannabinoids in medicine Part 2: Pain

      11 October 2019 Open Access Government
    • Cannabinoids in medicine Part 1: Cancer

      22 August 2019 Open Access Government
    • An interview with Neil Mahapatra

      08 January 2019 The Times Magazine
    • High life: the start-up hoping to unlock the secrets of medical cannabis

      09 August 2018 Evening Standard
    • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

      28 June 2018 OCT Press Release
    • Embracing the medical potential of cannabinoids

      01 June 2017 The Medicine Maker
    • Smashing the stigma with science

      01 June 2017 The Medicine Maker
    • Oxford University launches £10m research project into medical marijuana

      16 March 2017 Evening Standard
    • Oxford University to launch study on medical benefits of marijuana

      16 March 2017 The Telegraph
    • Oxford University to launch multimillion-dollar medical marijuana research program

      16 March 2017 CNBC
    • Oxford University launches £10m marijuana research programme

      16 March 2017 BBC
    • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

      15 March 2017 OCT Press Release